Past Press Releases - Trophos SA

October 2, 2013
Trophos announces final patient completion of Phase II Proof-of-Concept study of TRO40303 in ...
Trophos announces final patient completion of Phase II Proof-of-Concept study of TRO40303 in patients treated for acute myocardial infarction. More

October 11, 2012
Trophos program boosted by EUR 1 million grant for olesoxime in progressive Multiple Sclerosis
Agence Nationale de la Recherche awards second grant to Trophos led consortium for Phase Ib/IIa clinical study More

July 23, 2012
Trophos appoints JSB Partners as global partnership advisor
Life science advisor to advise Trophos on strategic partnerships for orphan disease and niche indication candidates. More

February 24, 2011
Trophos successfully completes phase 1 study for novel cardioprotective compound, TRO40303
Phase 2 Proof-of-Concept study in acute myocardial infarction planned for second half 2011 with MitoCare EU consortium. More

November 24, 2010
Trophos and MS-Repair partners present promising data on novel approach in multiple sclerosis
Oral presentation at the Society for Neuroscience congress highlights novel compounds to promote axon repair and remyelination in multiple sclerosis More

November 22, 2010
Trophos and the MitoTarget Consortium demonstrate potential of modulating mitochondrial dysfunction
Trophos and the MitoTarget Consortium demonstrate potential of modulating mitochondrial dysfunction in the treatment of neurodegenerative diseases More

March 17, 2010
Trophos completes patient enrolment in pivotal phase 3 efficacy study of olesoxime in ALS
Trophos completes patient enrolment in pivotal phase 3 efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease). More

September 29, 2009
Trophos launches the new generation of its fast plate imaging instrument, the Plate RUNNER HD
Trophos targets opportunities with instrument manufacturers and vendors for well-proven system that plugs market gap in fast high resolution imaging. More

June 5, 2008
Trophos completes enrolment of Phase II Clinical Trial of TRO19622 in painful peripheral ...
Trophos completes enrolment of Phase II Clinical Trial of TRO19622 in painful peripheral diabetic neuropathy More

May 29, 2008
Trophos demonstrates analgesic activity of neuroprotective agent TRO19622 in preclinical models
Trophos demonstrates analgesic activity of neuroprotective agent TRO19622 in preclinical models of painful peripheral neuropathy More

May 15, 2008
Trophos starts phase II clinical trial of TRO19622 in liver disease
Neurodegenerative disease specialist enrolls European Phase II of lead molecule in patients with Nonalcoholic Steatohepatitis More

September 28, 2007
Trophos starts phase Ib clinical trial of TRO19622 in spinal muscular atrophy
Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurological disorders, announced today that the company has begun enrolling Spinal Muscular Atrophy patients in a Phase Ib clinical trial of its lead product, TRO19622. More

September 4, 2007
Trophos Closes EUR 8.5 Million in Series C Funding
Proceeds to fund TRO19622 and TRO40303 to clinical proof of concept for neurological, ischemia-reperfusion injury and liver disease indications More

May 30, 2006
Trophos appoints Jacques Essinger as President of Supervisory Board
Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurodegenerative diseases, announced today the appointment of Jacques Essinger, PhD, as President of its Supervisory Board. More